•	
	;
	V

# STATE OF CONNECTICUT DEPARTMENT OF PUBLIC HEALTH

JUNE 12, 2002

IN RE:

DECLARATORY RULING
PROCEDURE ON THE
INTERPRETATION AND

APPLICABILITY OF VARIOUS STATUTES AND REGULATIONS CONCERNING THE SALE OF CONTACT LENSES

\* \* \* \* \* \* \* \* \* \* \* \*

CONNECTICUT BOARD OF EXAMINERS FOR OPTICIANS

BEFORE: RAYMOND DENNIS, LO, CHAIRPERSON

ANN TOSCA, MEMBER

ALBERT WINNICK, LO, MEMBER

FOR THE BOARD:

EILEEN MESKILL, ATTORNEY Assistant Attorney General

55 Elm Street

Hartford, Connecticut 06106

#### APPEARANCES:

FOR JOHNSON & JOHNSON VISION CARE, INC.:

HOWREY, SIMON, ARNOLD & WHITE, LLP 1299 Pennsylvania Avenue, NW Washington, D.C. 20004 By: MARGARET M. ZWISLER, ATTORNEY

#### APPEARANCES (CONT.):

FOR 1-800 CONTACTS, INC.:

THE FURTH FIRM, LLP
Furth Building, Suite 1000
201 Sansone Street
San Francisco, California 94104
By: THOMAS DOVE, ESQUIRE

AXINN, VELTROP & HARKRIDER, LLP
90 State House Square
Hartford, Connecticut 06103-3702
By: WILLIAM M. RUBENSTEIN, ESQUIRE
ERIC PALMQUIST, ESQUIRE

FOR CONNECTICUT ASSOCIATION OF OPTOMETRISTS:

FRANKEL AND THORNBERRY
3000 Main Street
Stratford, Connecticut 06614
By: ROBERT FRANKEL, ESQUIRE

FOR THE OFFICE OF THE ATTORNEY GENERAL:

STEVEN M. RUTSTEIN, ESQUIRE Assistant Attorney General 110 Sherman Street Hartford, Connecticut 06105

FOR INTERVENOR, CONNECTICUT BOARD OF EXAMINERS FOR OPTOMETRISTS:

LEORA BERNS, O.D. Connecticut Board of Examiners for Optometrists 410 Capitol Avenue, MS #13PHO Post Office Box 340308 Hartford, Connecticut 06134-0308

FOR INTERVENOR, FEDERAL TRADE COMMISSION:

J. HOWARD BEALES, III, Director,
Bureau of Competition
R. TED CRUZ, Director, Office of Policy Planning
MAUREEN K. OHLHAUSEN, ATTORNEY
JOHN T. DELACOURT, ESQUIRE
600 Pennsylvania Avenue, NW
Washington, D.C. 20580

POST REPORTING SERVICE HAMDEN, CT (800) 262-4102

#### APPEARANCES (CONT.):

FOR INTERVENOR, CONNECTICUT SOCIETY OF EYE PHYSICIANS:

WILLIAM EHLERS, M.D.
DEBORAH A. OSBORN, Executive Director
26 Sally Burr Road
Post Office Box 854
Litchfield, Connecticut 06759-0854

FOR INTERVENOR, AMERICAN ACADEMY OF OPHTHALMOLOGY:

DORSEY & WHITNEY, LLP 60 South Sixth Street, Suite 1500 Minneapolis, Minnesota 55402-1498 By: JAMES B. LYNCH, ESQUIRE

FOR INTERVENOR, CONNECTICUT OPTICIANS ASSOCIATION:

RENE R. RIVARD, Executive Director 945-B Cromwell Avenue Rocky Hill, Connecticut 06067

1	· Verbatim Proceedings of a Declaratory
2	Ruling Proceeding on the Interpretation and Applicability
3	of Various Statutes and Regulations Concerning the Sale
4	of Contact Lenses, before the State of Connecticut, Board
5	of Examiners for Opticians, held at the Legislative
6	Office Building, 410 Capitol Avenue, Hartford,
7	Connecticut, on June 12, 2002, at 9:10 A.M., at which
8	time the parties were represented as hereinbefore set
9	forth
10	
11	
12	
13	
14	CHAIRPERSON RAYMOND DENNIS: My name is
15	Raymond Dennis. I'm Chairman of the Board of Examiners
16	for Opticians. I'd like to introduce the other members
17	of our Board first.
18	To my immediate left, Ann Tosca, our
19	public member. To her left, Al Winnick, a professional
20	members. To my right, representing us today the
21	Assistant Attorney General Eileen Meskill.
22	I'm just going to make a brief statement
23	to get started and then we'll get on with the
24	proceedings. We're here this morning to conduct a

1	the Federal Trade Commission.
2	I'd like to start with the swearing in
3	please.
4	(Whereupon, Mr. R. Ted Cruz was duly sworn
5	by the Court Reporter.)
6	COURT REPORTER: Would you state and spell
7	your name for the record please?
8	MR. CRUZ: My name is Ted Cruz, C-r-u-z,
9	T-e-d. And I'm the Director of the Office of Policy
10	Planning at the Federal Trade Commission. With me is
11	Jerry Ellig, who is the Deputy Director of the Office of
12	Policy Planning and PhD economist who is also available
13	and was one of the co-authors of the FTC report here.
14	The testimony we are providing today and
15	the written testimony that the FTC provided to this Board
16	is the statement of the staff of the Office of Policy
17	Planning and the staff of the Bureau of Consumer
18	Protection.
19	Staff comments are something that the FTC
20	does in a wide number of areas and it's how we typically
21	comment on proceedings in state and local matters. And
22	those comments are the official position adopted by the

Office of Policy Planning, which is an office that has

policy overview for the entire agency of the FTC, and

23

24

1	they are they position of the Bureau of Consumer
2	Protection, which again has responsibility for consumer
3	protection across the agency.
4	In addition, the comments were approved by
5	the full Commission. The written comments that we
6	submitted to you in March were approved by a four-to-
7	nothing vote, unanimous vote of the Commission. One
8	Commissioner was unavailable for that vote.
9	And my testimony and Dr. Ellig's testimony
10	before you today was approved unanimously, five-zero,
11	with the Commission authorizing us to come and provide
12	this oral testimony.
13	Rather than summarize what we said in
14	writing, which I believe lays out the position of the
15	staff of the Federal Trade Commission in considerable
16	detail, what I'd like to do is just really hit the high
17	points of what we think is important for this Board to
18	consider.
19	And I'd like to begin by observing just a
20	big question; why we're here. Why is the FTC coming
21	before your Board and devoting substantial staff and
22	Commission resources to sharing our opinions with this
23	Board?

And the reason that the FTC felt it made

24

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

sense to come in here and provide that advice is that the staff are concerned that the potential rulings in this proceeding could have a significant impact on Connecticut consumers. And the FTC's statutory mission is to protect consumers, to protect consumers in Connecticut and to protect consumers nationwide. And our statutory mission is also to preserve competition.

There is a concern on the part of the staff of the FTC that the rulings of this particularly if those rulings were then followed by boards of other states, could have a significant and detrimental impact nationwide to consumers and And it was that concern that led competition. the Commission and the staff to come before you today.

In addition, the Commission has extensive experience in the eye care industry. The Commission has been very active in the eye care industry for a number of decades and there's a great deal of institutional experience both in attorneys and economists at the Federal Trade Commission.

In large part, much of this dispute before you today that we've seen hashed out in the Discovery disputes and everything else it seems to us is part and parcel of a larger dispute and a dispute principally

between private parties, two private parties in particular, Johnson & Johnson and 1-800 Contacts, that have been engaged in a rather lengthy and at times rather acrimonious dispute.

The suggestion of the staff of the FTC is that this Board would best serve Connecticut consumers by leaving that dispute to those parties and letting them fight it out between each other and to act upon the petition here by ruling that Connecticut Statutes and Regulations require licensing and require prescriptions and, in particular, depending on how prescriptions are required -- and I'll explain that a little bit more in a moment. It is the position of the staff and the FTC that that could have significant to detrimental impact on Connecticut's consumers.

Now, I want to clarify that the FTC does not have a position on the proper interpretation of Connecticut Statutes and Regulations. It is not our role or, frankly, our competence to come before you and argue what a particular Connecticut Statute or Regulation means. That is a role much better entrusted by statute to this Board and much better suited to the Attorney General's Office and to the private parties who are here litigating that matter.

1	Rather, what the Commission is doing is
2	recognizing that when any regulatory board is addressing
3	statutory matters and regulatory matters, there is often
4	a considerable amount of discretion in how statutes and
5	regulations are applied.
6	And in applying that discretion, this
7	Board is entitled to consider the public interest. And
8	so the purpose of our comment is to comment on the public
9	interest and what the likely impact of a ruling by this
10	Board will be upon Connecticut consumers.
11	We'd like to make three general points.
12	First, the current regulation, in the judgment of the
13	staff of the Federal Trade Commission, is sufficient to
14	deal with the public health concerns that are raised by
15	the sale of contact lenses.
16	A great deal of material has been
17	submitted to this Board about the health risks that can
18	accompany the use of contact lenses. But there are a
19	number of things that are not before this Board but
20	nonetheless are being discussed in the abstract.
21	Nothing before this Board would affect
22	quality standards for the manufacture of contact lenses.
23	Nothing before this Board would reflect or affect
24	standards of use, when contacts are worn, for how long,

1 under what conditions. Nothing before this Board would 2 affect standards of medical examinations, when 3 optometrists or ophthalmologists would prescribe contacts, what contacts they would prescribe. nothing before this Board would affect fraud or deception 5 6 in the sale or delivery of contact lenses.

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

For all of those, there are extensive regulatory protections, such that if a seller of contact lenses, for example, were engaged in fraud or misleading representations to consumers, I am sure the Connecticut Attorney General's Office would take that very seriously. And I can tell you that the Federal Trade Commission would as well, given that our statutory mission is to protect consumers and, in particular, to protect them from fraud and deception.

The question before this Board is really a lot more narrow and it involves a sub-set principally which is stand-alone sellers of replacement lenses, which, as we explained in our written comment, is a more recent development in the evolution of the eye care world, such that many of the tasks that one thinks of an optician carrying out are not carried out by stand-alone sellers of replacement lenses.

24 Opticians are highly trained

professionals. A stand-alone seller of replacement lenses is taking sealed boxes off a shelf in a warehouse and dropping them in a FedEx packet.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

And the question before this Board with respect to licensing is if that task, taking a sealed box from a shelf and dropping it in the FedEx package, if that task needs to be supervised by a Connecticut optician; if a professionally trained optician needs to stand and supervise, either directly or indirectly, the taking of that sealed package and moving it into a mailing package. And as we have suggested in our comment, we do not believe the answer to that should be Yes.

A second point I'd like to address very briefly -- and Jerry Ellig is available to address it in considerable more length -- is in deciding whether to require licensing part of that decision should measure the benefits of licensing to the incremental costs. it is the judgment of the staff of the Federal Trade Commission that the likely costs to Connecticut consumers, to consumers nationwide if these regulations are replicated in other boards following your example, and to competition are all likely to be significant and that the benefits of requiring licensing are not likely

to be significant. And, as I've said, Jerry Ellig is available when I'm completed to elaborate on that point.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

also want to address a matter clarification. In the briefs. Johnson & Johnson represented that the Federal Trade Commission confirmed that their view that the commerce clause is not obstacle to applying licensing beyond the borders of the state of Connecticut. And to clarify the record, that is not correct. The staff of the Federal Trade Commission did not confirm anything to that effect.

And we have brought with us today in writing a clarification, a letter to this Board making clear that our brief did not state that. And I have that available for the Board here today, as well as copies for the parties.

MS. ZWISLER: I would object to him handing this out on this -- on no notice at all to me and it would be impossible for me to effectively cross examine on this because I guarantee to you that it is a reversal of what they said in the brief. And I'm going to need time to read that and read the brief and demonstrate to you that that's so. If you'd like to accept it, that's fine. But then I need to defer my Cross Examination of this witness to prepare for this

1

20

21

reversal.

- 2 MR. CRUZ: I would note that this letter 3 is a four-paragraph letter that simply states that was 4 not our position. And it responds to the position 5 Johnson & Johnson took in its reply brief long after the submission of our brief. 6 And it simply clarifies that 7 they have mischaracterized our position and we do not 8 take the position they ascribe to it. 9 I think upon seeing the letter, I'm guite 10 confident that Ms. Zwisler can cross examine as much as 11 she likes to the statement that that is not our position. 12 And the letter simply makes that clear. 13 MS. ZWISLER: Written testimony needs to 14 be submitted seven days before this hearing. And I think 15 it's completely improper and I object. 16 In addition to my objection that I don't 17 have on the fly the ability to read the document and 18 listen to him talk and then cross examine him, I think 19 that's terrifically unfair.
- MS. MESKILL: Well, I do think you obviously have to give her a copy of the letter. I'd like to know -- I think we will take a break. But before

MR. RUBENSTEIN:

break and have Ms. Zwisler read the letter.

Maybe we should take a

- we do that, I'd like to know if you know what page of the
- 2 brief, so I can go back and look at it, to what you're
- 3 talking about.
- 4 MR. CRUZ: That's Page 18 of the reply
- 5 brief, which the opening paragraph -- the opening
- 6 paragraph is a letter, cites --
- 7 MS. MESKILL: Okay. Thank you. Of the
- 8 original brief?
- 9 MR. CRUZ: Of the reply brief.
- MS. MESKILL: Of the reply brief.
- 11 CHAIRPERSON DENNIS: I have five minutes
- after 2:00. At 2:15, we'll reconvene.
- 13 (RECESS)
- 14 CHAIRPERSON DENNIS: Okay. Since we have
- in our break had the opportunity to, at the very least,
- 16 allow some opportunity for you to review the document
- 17 provided by the FTC, I'd like to ask you if you want to
- 18 restate your objection or --
- MS. ZWISLER: No. Thank you for the
- 20 break. That's permitted me to read the letter and to
- 21 find where it's inconsistent with the report. And I'll
- 22 deal with that on Cross Examination.
- CHAIRPERSON DENNIS: Okay. Fine. So
- you're no longer objecting to the admittance of this

1	document. Is that correct?
2	MS. ZWISLER: That's correct, Mr.
3	Chairman.
4	CHAIRPERSON DENNIS: Then that means that
5	we all get a copy of it. Is that correct?
6	MS. MESKILL: Okay. Right. Let me just
7	find they are Intervenor 2. This will now be I-2-B.
8	And that's the letter dated June 11, 2002.
9	(Whereupon, the FTC letter dated June 11,
10	2002 was received and marked into evidence as Intervenor
11	2 Exhibit B.)
12	MS. MESKILL: I'm sorry. I just put the
13	mike back on. That will be I-2-B.
14	CHAIRPERSON DENNIS: Okay. And, again
15	and I did have this conversation briefly with you, sir,
16	regarding the ten-minute time limit we gave for
17	statements. And I think we're at about two minutes left
18	here. So if you'd be kind enough to sum up your
19	MR. CRUZ: Sure. I will wrap up with my
20	final point, which is on the third question before this
21	Board, concerning a prescription requirement. The staff
22	of the Federal Trade Commission takes no position on the
23	existence or not of a Federal or Connecticut State
24	prescription requirement or on, if there is such a

1 requirement, when it is implicated and when it is not.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

What we do take a position on is if this Board determines that there is a Connecticut prescription requirement, that there is a substantial amount difference in how any such prescription requirement is interpreted. And the way a prescription requirement is interpreted can either have pro-competitive or competitive effects. And, in particular, the way the requirement that a seller selling contact lenses receive a prescription is interpreted can be interpreted either pro-competitively or anti-competitively.

Johnson & Johnson has already backed away from their initial petition where they suggested that a prescription must be an original in writing, signed by a physician or optometrist to -- which would be the least pro-competitive interpretation of what receipt of prescription means.

They have now moved to receipt of a written prescription or verification with the individual that issued the prescription.

We would point out that beyond that there are additional ways that a prescription requirement could be interpreted that include accepting the representations of a customer, which this Board could determine is

sufficient to qualify as receipt of a prescription, or, as we suggested in our comment, this Board could determine -- could presume that receipt of information from the customer, along with providing the issuing optometrist an opportunity to correct any errors, is sufficient.

I would note that a number of the filings talked about the particular practices of 1-800 and others and said that some of the calls asking for verification don't include the name of the customer, don't include a number back. The staff of the FTC doesn't know what 1-800's business practices are. But that's certainly a legitimate inquiry whether there is a reasonable mechanism for verification.

But, that being said, particularly given the significant possibility that the individual optometrist might refuse to affirmatively confirm, it would be a reasonable determination for this Board to make that a prescription can be presumed received if the customer gives that information to the seller and the seller contacts the issuing optometrist and gives a reasonable opportunity to correct any errors.

Finally, what we would say is that in interpreting your statutes and regulations there is

1	frequently a great deal of leeway. And the staff of the
2	Federal Trade Commission would urge this Board in
3	considering that leeway and in exercising its discretion
4	to consider the welfare of Connecticut consumers and
5	maximizing that welfare and maximizing competition so
6	that consumers can receive high-quality goods at low
7	prices with the least convenience. And so consumer
8	choice and competition can be respected.
9	Thank you.
10	CHAIRPERSON DENNIS: Thank you.
11	And we'll start with Cross Examination
12	with Johnson & Johnson.
13	MS. ZWISLER: Thank you.
14	
15	R. TED CRUZ
16	having been called as a witness, having been duly sworn,
17	testified on his oath as follows:
18	
19	CROSS EXAMINATION
20	BY MS. ZWISLER:
21	Q Mr. Cruz, your opinion, basically, or your
22	testimony to the Board is that the FTC believes that if
23	the Board interprets its laws restrictively, there is
24	likely to be a significant adverse effect. Is that what